A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）

Inclusion Criteria: * Subjects who understand and voluntarily sign the Informed Consent Form（ICF） before the enrolment; * Age: 40-65 years old, both genders; * Diagnosis of knee osteoarthritis based on American College of Rheumatology criteria; * Subjects with KOA who have persistent pain for more than six months * Kellgren-Lawrence grade: II-III Exclusion Criteria: * Subjects previously diagnosed of secondary knee osteoarthritis, or those diagnosed with hip/ankle joint disease requiring medical intervention; * Suffering from other diseases that impair knee function or joints; * Have received stem cell therapy; * Have knee injury history; * Experienced knee surgery, or plan to undergo knee surgery; * Received analgesics to relieve pain before Investigational Medicinal Product(IMP) injections; * Have used traditional Chinese medicine to treat KOA within 4 weeks; * Have used intra-articular injection of drugs to treat KOA within 12 weeks; * Received glucosamine,chondroitin sulfate, or diacetate therapy before investigational drug intervention within 12 weeks; * Subjects with acute phase of knee osteoarthritis; * Severe deformity of the knee; * Known or suspected allergy or a history of allergies; * Abnormal results of laboratory examination as follows: Hepatic Insufficiency （Alanine Aminotransferase\>2xULN or Aspartate aminotransferase \[ast\]\>2xULN) renal dysfunction (creatinine clearance rate ≤60ml/min or blood urea nitrogen(BUN) \> 2× ULN), Coagulation Defects (INR \> 1.5) or severe hematological diseases (Grade 3 or above anemia \[Hb \< 8 g/dL\], Grade 2 or above thrombocytopenia platelet count(PLT) \< 75×10\^9/L) ; * BMI≥30kg/m\^2 * Severe systemic infection or local knee joint infection; * Have received systemic glucocorticoid therapy before intervention or need to take systemic glucocorticoid therapy during the treatment; * Have a history of acute myocardial infarction or severe heart diseases,QT prolongation; * Subjects with peripheral or central nervous system disorders that may interfere assessments; * Have contraindications to Magnetic Resonance Imaging(MRI) * Subjects who are unable to walk on his own; * Subjects with alcohol/drug addiction/abuse or mental disorders; * Pregnant or lactating, or unable to comply with contraceptives within 6 months after end of study; * Have participated in other clinical trials within 12 weeks before the screening; * Severe and poorly controlled comorbidities;